Low BRCA1 correlates with ERCC1 mRNA and predicts a favorable outcome in locally advanced NSCLC patients treated with cisplatin/gemcitabine, followed by surgery [42]. The gene discussed is ERCC1; the disease is non-small cell lung carcinoma.